1. Introduction {#sec0005}
===============

Dendritic cells (DCs) are professional antigen-presenting cells with nonredundant functions in both innate and adaptive immunity. While patrolling peripheral tissues, DCs sample antigens and integrate environmental cues regarding the nature of the threats they encounter to initiate appropriate immune responses. Dendritic cells develop in the bone marrow (BM) through different progenitor stages in a tightly regulated transcriptional process ([@bib0480]) and reviewed elsewhere in this issue) giving rise to plasmacytoid DCs (pDCs) and pre-conventional DCs (pre-cDCs). However, the DC nature of pDCs is currently challenged as they have also been shown to differentiate from lymphoid cell progenitors ([@bib0105]; [@bib0125]; [@bib0395]). As these cells are discussed in detail in other reviews in this issue, we will focus this review on conventional DCs (cDCs). Upon their egress from the BM, pre-cDCs seed lymphoid and most non-lymphoid tissue where they further differentiate into cDCs driven by environmental cues and the concerted actions of transcription factors (TFs) ([@bib0480]). Both the development, homeostasis and function of cDCs requires Fms-related tyrosine kinase 3 (Flt3) receptor signaling ([@bib0165]; [@bib0185]; [@bib0375]; [@bib0555]). Based on differences in transcriptional control, specialized function, phenotype and ontogeny, mature cDCs are further subdivided into cDC1s and cDC2s ([@bib0200]).

Transcriptionally, cells of the cDC1 and cDC2 lineages are commonly distinguished based on their mutually exclusive expression of interferon-regulatory factor 8 (IRF8) and IRF4 respectively ([@bib0205]; [@bib0355]). Functionally, cDC1s excel in antigen cross-presentation to CD8 T cells, whereas cDC2s typically drive CD4 T cells toward distinct effector subsets. While the cDC1 subset is precisely delineated by the expression of specific markers (such as XCR1) and relies on a distinct set of TFs, cDC2s seem more heterogenous on a transcriptional level and express surface markers (such as SIRPα and CD11b) that often overlap with macrophages and monocyte-derived cells (MCs) ([@bib0205]).

Already in the BM pre-cDCs become gradually committed to the cDC1 or cDC2 fate and enter the bloodstream as pre-cDC1s and pre-cDC2s respectively ([@bib0055]; [@bib0195]; [@bib0320]; [@bib0430]; [@bib0455]; [@bib0535]). Guided by tissue-specific signals, such as those derived from the local niche or invading pathogens, pre-cDCs and cDCs alter their transcriptional profile that dictates a functional module best suited to deal with the requirements of the current microenvironment ([@bib0400]). This can result in a change of surface markers and/or dependency on certain TFs to exert these functions, and as such cDCs may obtain a maturation state different from the classically defined subset. In this review we will focus on recent findings regarding the factors that regulate this fate decision and the functional adaptations of the different cDC subsets.

2. Irf8 and Batf3 {#sec0010}
=================

*Irf8*, formerly known as interferon consensus binding protein (ICSBP) plays an important lineage-determining role in the BM at several developmental stages of monocytes, pDCs and cDC1s ([@bib0030]; [@bib0130]; [@bib0195]; [@bib0260]; [@bib0355]; [@bib0475]). The action of IRF8 at the macrophage and DC precursor (MDP) and common monocyte/macrophage precursor (cMoP) stages is crucial for monocyte development and the exclusion of granulocyte potential ([@bib0255]; [@bib0475]). Beyond the cMoP stage, *Irf8* is redundant for the survival of monocytes or monocyte-derived cells (MCs) ([@bib0250]; [@bib0475]), yet the functional role of IRF8 in these cells remains largely unknown.

By conditionally deleting *Irf8* at different stages of DC development, *Irf8* has been shown to be a terminal selector for cDC1s as it is required for the specification of pre-cDCs toward terminally differentiated cDC1s ([@bib0040]; [@bib0195]; [@bib0310]; [@bib0475]) and that its continuous high expression through BATF3-mediated autoactivation is required to maintain the identity of cDC1s ([@bib0195]). Two recent reports by the Murphy lab, deleting specific enhancers within *Irf8* and employing a genetic epistasis strategy, ([@bib0030]; [@bib0130]) have offered insights in the mechanism and functional hierarchy of TFs involved in *Irf8* expression and subsequent DC fate specification. The *Irf8* gene carries three distinct enhancers bound by specific TFs that regulate *Irf8* at different stages during development ([@bib0130]). Binding of the TF PU.1 to the −50 kb (relative to the *Irf8* transcriptional start site) enhancer was shown to regulate *Irf8* levels in mature monocytes and some macrophages populations ([@bib0130]), but was not required for *Irf8* expression in MDPs or for the downstream DC populations as previously reported ([@bib0435]). The +41 kb *Irf8* enhancer likely activated by E2A (encoded by *Tcf3*) is required to specify common DC precursors (CDPs) to pre-cDC1s by promoting IRF8 expression. In addition, the +41 kb *Irf8* enhancer is also required for normal pDC phenotype with *Irf8* +41kb^-/-^ pDCs having a similar phenotype to *Irf8*^-/-^ pDCs ([@bib0130]; [@bib0475]) potentially through binding another E protein, E2-2 (encoded by *Tcf4*), the lineage-determining TF of pDCs ([@bib0095]). Once IRF8 expression is induced in cDC1-committed progenitors, the +32 kb *Irf8* enhancer, which is activated by BATF3 and IRF8 itself ([@bib0195]), becomes active in the pre-cDC1 stage, promoting both their transition to mature cDC1s and their maintenance by sustaining IRF8 expression. This essential switch from the E2A-dependent +41 kb *Irf8* enhancer in DC progenitors to the BATF3-dependent +32 kb enhancer in mature cDC1s depends on a NFIL3-ZEB2-ID2 regulatory circuit in which NFIL3 enforces ID2 expression by suppressing ZEB2 (see below) ([@bib0030]). Ultimately, ID2 inhibits the E2A activity at the +41 kb *Irf8* enhancer from the pre-cDC1 stage onwards, thereby mediating the switch to the BATF3-controlled +32 kb *Irf8* enhancer in mature cDC1s.

As the +32 kb enhancer is absolutely required for cDC1 development, the +32 kb^−/−^ mice generated as part of this study ([@bib0130]) represent a nice tool to further study cDC1 function, without compensatory mechanisms at play as previously observed for the loss of *Batf3*, *Nfil3* and *Id2* ([@bib0460]). Nevertheless, studies using *Batf3* or *Irf8* KO mice have put forward the cDC1 branch as a major cellular source of IL-12 in several models of infection with intracellular pathogens ([@bib0145]; [@bib0215]; [@bib0325]; [@bib0330]; [@bib0410]; [@bib0415]). This may result from the constitutive expression of *Irf8* in cDC1s ([@bib0015]; [@bib0145]; [@bib0475]), as *Irf8* has previously been suggested to play a role in the expression of *Il12*-genes in macrophages, ([@bib0295]; [@bib0410]; [@bib0540]). However, as it is not possible to uncouple *Irf8* expression and IL-12 production by cDC1s (cDC1s do not develop in the absence of *Irf8)* this remains to tested. As cDC2s can also express *Il12b* ([@bib0230]; [@bib0405]; unpublished data) and IFN-γ driven IL-12 production by MCs is important at sites of infection ([@bib0190]), the dependence on IRF8 for IL12 production in these cells should also be examined. Interestingly, it has been proposed that IL-12 produced by peripheral DCs upon infection can activate NK cells in the BM, that in response produce IFN-γ locally ([@bib0020]). One could envisage that such an altered milieu in the BM could also induce epigenetic or even transcriptional changes in the DC precursors biasing the generation toward specific progeny on demand of the biological need. As recent reports in both mice and humans have demonstrated that IRF8 expression as early as the multipotent progenitor stage marked cells biased toward the cDC1 lineage ([@bib0265]; [@bib0280]), it would be interesting to further investigate whether such priming of precursors actually takes place under different settings.

As cDC1s typically do not develop in *Irf8* and/or *Batf3* deficient mice, it is challenging to assess any additional functional role(s) for these TFs in mature cDC1s. However, the requirement for BATF3 to sustain IRF8 expression can be compensated for by *Batf* and *Batf2* binding the same +32 kb *Irf8* enhancer ([@bib0130]) in certain conditions ([@bib0460]; [@bib0505]). The BATF3 dependency can also be artificially bypassed by crossing *Batf3* knock-out (Batf3^−/−^) mice with transgenic *Irf8^VENUS^* mice, which have an increased copy number of endogenous *Irf8* ([@bib0195]; [@bib0500]). By comparing *Batf3^+/+^ Irf8^VENUS+^* and *Batf3^-/-^ Irf8^VENUS+^* cDC1s, a role for BATF3 in cDC1-mediated tumor rejection was uncovered, as BATF3 was found to specifically target a small set of genes required by cDC1s to carry out this function ([@bib0500]). Additionally, administration of exogenous IL-12 in *Batf3^-/-^* mice has also been shown to restore cDC1 development and the capacity to cross-present antigen and mediate tumor rejection ([@bib0505]). This suggests that IL-12 provides additional signals, absent in *Batf3^-/-^ Irf8^VENUS+^* mice, that can compensate for impaired tumor rejection ([@bib0500]), although the transcriptional program that dictates this compensation remains elusive.

3. Irf4 {#sec0015}
=======

IRF4 is preferentially expressed by cDC2s ([@bib0205]) and was originally proposed to be required for the specification of BM progenitors toward splenic CD4^+^ cDCs or CD11b^hi^ cDCs ([@bib0490]; [@bib0495]). Although full *Irf4* deficient mice have a reduced number of cDC2s in most tissues ([@bib0205]), conditional deletion of the *Irf4* gene in CD11c-expressing cells resulted in an altered surface marker expression profile and functional deficits ([@bib0040], [@bib0035]; [@bib0240]; [@bib0385]; [@bib0425]) of the cDC2 lineage but does not result in the loss of the entire population. Thus while IRF4 controls some aspects of cDC2 specification, it, unlike IRF8 in cDC1s, is not absolutely required for the presence of the entire cDC2 lineage. Phenotypically, loss of *Irf4* from the pre-cDC stage on in *Irf4^fl/fl^* mice driven by an 'early-acting' *Itgax*-Cre ([@bib0085]) resulted in a reduction (although not complete ablation) of specific cDC2 subtypes expressing CD24 in the lung ([@bib0005]; [@bib0040]; [@bib0425]) and the heart ([@bib0515]), both CD24 and CD103 in the intestine ([@bib0385]; [@bib0425]), CD103b (MGL2) in the skin ([@bib0170]) and CD4 in the spleen ([@bib0040]; [@bib0490]; [@bib0495]), although whether this reduction is due to a lack of development or impaired survival (see below) remains unclear. Functionally, IRF4 appears to control CCR7-mediated migration of peripheral cDC2s to the draining lymph nodes (LNs) ([@bib0005]; [@bib0010]; [@bib0040], [@bib0035]; [@bib0100]; [@bib0520]; [@bib0565]) and favors a transcriptional module that governs MHCII-dependent antigen presentation required for T cell priming ([@bib0400]; [@bib0525]). IRF4 promotes the expression of cathepsin S, H2-Oa and H2-DM, which are involved in antigen loading into the peptide-binding pocket of MHC class II molecules ([@bib0075]; [@bib0525]). In addition, IRF4 was found to negatively regulate *March1*, preventing MHCII surface expression ([@bib0465]), and *Cystatin C*, which in turn inhibits the activity of cathepsin S ([@bib0390]; [@bib0525]). Therefore is tempting to speculate that a drop in IRF4 levels in murine lung cDC1s and cDC2s induced upon resolution of pneumonia, could be causally associated with the impaired innate and adaptive immune responses against a secondary bacterial infection ([@bib0400]). Moreover, *in vitro* cDC2-like cells and MCs induced by GM-CSF and IL-4 required IRF4 to prime CD8^+^ T cells ([@bib0060]), opposed to *in vivo* cDC1s that rely on IRF8 and BATF3 for efficient cross-presentation. Aside from roles in antigen presentation and migration, IRF4 in cDC2s may also antagonize apoptosis ([@bib0385]; [@bib0425]; [@bib0480]). Thus, it remains unclear whether *Irf4*-deficient cDC2s fail to migrate because *Ccr7* is directly regulated by IRF4 and hence they die in the tissue unable to migrate or if they die prematurely before they can acquire CCR7 expression. Evidently, the induction of cytotoxic or T helper (Th) responses requires efficient MHCI or MHCII presentation of transferred antigen in the LN. Therefore the impaired survival and/or migration of specific subsets of *Irf4*-deficient cDC2s could, at least partially, explain the deficient priming of CD4 T cells to Th2 ([@bib0170]; [@bib0560]; [@bib0585]), Th17 ([@bib0385]; [@bib0425]), T regulatory (Treg) ([@bib0005]; [@bib0530]) or T follicular helper (Tfh) subtypes ([@bib0155], [@bib0160]; [@bib0240]) that has been reported. Aside from CD4 T cell priming, upon viral infection or specific PRR signals, cDC2s can also function in CD8 T cell priming (unpublished and [@bib0005]; [@bib0050]; [@bib0115]; [@bib0225]; [@bib0470]), however, the underlying transcriptional program that licenses cDC2s to initiate CD8 T cell responses remains to be elucidated. Next to its role in survival and/or migration, some reports indicate that IRF4 could also intrinsically control a functional gene module in cDCs that drives Th specification under certain circumstances ([@bib0005]; [@bib0010]; [@bib0080]; [@bib0155], [@bib0160]; [@bib0240]; [@bib0270]; [@bib0340]; [@bib0350]; [@bib0365]; [@bib0385]; [@bib0425]; [@bib0445]; [@bib0530]; [@bib0560]).

4. Cooperation with Irf4 and Irf8 {#sec0020}
=================================

It was recently shown in humans that the discrimination between pre-cDC1s and pre-cDC2s correlated with the ratio of IRF8 to IRF4 expression, indicating that the combinatorial dose of these TFs determines fate decision ([@bib0320]; [@bib0535]). Furthermore, reciprocal expression of IRF4 and IRF8 in pre-cDC subsets might directly prime distinctive molecular programming of the progeny, thereby promoting the presentation of antigens *via* the MHCII or I pathway, respectively ([@bib0525]). Since antagonism between IRF4 and IRF8 has been demonstrated in activated B cell differentiation ([@bib0575]), it is tempting to assume that competition between both TFs would also contribute to the fate decision between cDC1s and cDC2s. Further supporting this hypothesis, IRF4 is strongly increased in uncommitted pre-cDCs and committed pre-cDC2s in the absence of IRF8 which in turn might accelerate cDC2 development ([@bib0475]). In pDCs an increase in IRF4 expression compensated for the loss of IRF8 as IRF4^−/−^IRF8^−/−^ mice completely lacked pDCs ([@bib0475]). Next to the functional dichotomy of IRF8 and IRF4 in cDCs, both TFs similarly correlated with the expression of genes encoding MHCII, CD80, CD86 and CCR7 in cDC1 and cDC2 subsets, indicating that IRF8 and IRF4 also induce comparable aspects of DC maturation ([@bib0420]; [@bib0525]). Even though cDC2s are not quantitatively affected by *Irf8* or *Batf3* deficiency in steady state, expression of costimulatory molecules and MHCII dependent antigen presentation was found to be impaired in cDC2s derived from *Irf8*^−/−^ mice ([@bib0015]; [@bib0335]). Therefore, further research is warranted to investigate whether the loss of these subset-associated TFs could intrinsically affect the functional maturation of cDC2s under certain conditions, and *vice versa*.

5. Klf4 {#sec0025}
=======

Another TF associated with cDC2s is Kruppel-like factor 4 (KLF4). Interestingly, KLF4 has been shown to be required for a subpopulation of murine cDC2s. As such, *Itgax-Cre Klf4^fl/fl^* mice show a reduction of cDC2s across lymphoid and non-lymphoid tissues, although the missing cDC2 subsets differed in their surface expression pattern ([@bib0510]). For instance, loss of *Klf4* selectively eliminated cDC2s expressing CD24 and MGL2 (CD301b) in the lung, while compromising the development of migratory CD11b^−^CD24^−^ cDC2s in the skin. Functionally, these KLF4-dependent cDC2s appear essential for mounting Th2 responses to certain stimuli ([@bib0510]), consistent with reduced Th2 responses observed in reports using *Itgax-Cre Irf4^fl/fl^* and *Mgl2*-DTR mice ([@bib0170]; [@bib0245]). Notably, KLF4 is not alone in regulating a subset of cDC2s (see below).

6. Zeb1 and Zeb2 {#sec0030}
================

The ZEB proteins are a family TFs consisting of two members, ZEB1 and ZEB2 ([@bib0440]). While *Zeb1* is expressed across DC subsets in mice, *Zeb2* expression is found in murine pDCs and cDC2s, but absent in cDC1s ([@bib0345]; [@bib0440]). Despite its wide expression across the cDC lineage, the role of ZEB1 in cDCs and their progenitors remains largely unclear. *In vitro Zeb1* knock down in a murine tumor-derived DC cell line or FLT3L-induced BMDCs reportedly results in impaired activation and cytokine secretion and a Th2 biased response following DC:T cell coculture ([@bib0485]). Thus it will be interesting to determine if this is also the case *in vivo*. The other ZEB family member, ZEB2, was recently proposed to act as a switch at the bifurcation of cDC1 and pDC fate specification ([@bib0030]; [@bib0570]). However, it is currently questioned whether pDCs and cDC1s actually share a common progenitor, as it was proposed that pDCs may primarily develop from lymphoid progenitor cells independently of the myeloid cDC lineage ([@bib0125]). Nevertheless, it is clear that the presence of both cDC1s and pDCs rely on the mutually exclusive repression of either ZEB2 or ID2 in addition to their use of distinct *Irf8* enhancers (see above). Repression of ZEB2 by NFIL3 leading to increased ID2 expression is essential for cDC1 specification at the CDP stage ([@bib0030]; [@bib0570]), while in pDCs, ZEB2 is required for their development and maintenance ([@bib0450]; [@bib0570]), presumably through inhibition of ID2 which in turn antagonizes *Tcf4* expression ([@bib0180]). *Zeb2* is also consistently expressed throughout the development and maturation of the cDC2 lineage ([@bib0430]). Although loss of *Zeb2* only slightly affected cDC2 numbers in a cell-intrinsic manner, this effect varied between cDC2 subsets in different tissues ([@bib0450]; [@bib0570]), while *Zeb2^fl/fl^* mice crossed with a "late-acting" Itgax-Cre did not have a defect in cDC2 numbers. Taken together, these data suggest that ZEB2 may act early in cDC2 development, in a specific subset manner ([@bib0450]). In the future, the use of cDC subset-specific *Zeb2* deletion may help to unravel the cell-intrinsic effects of *Zeb2* deficiency on DC function.

7. Notch {#sec0035}
========

Apart from cell-intrinsic effects of certain TFs, tissue-specific signals, such as NOTCH ligands or lymphotoxin β (LTβ), can inform DCs of their surroundings and thereby guide their differentiation and function ([@bib0090]; [@bib0150]). NOTCH receptors transmit signals from membrane-bound ligands of the Delta-like (DL) and Jagged (Jag) families through the common TF RBPjk. It has been shown that NOTCH2-RBPjk signaling is involved in the terminal differentiation of a cDC2 subset expressing ESAM localized in the marginal zone bridging channels of the spleen and CD103 in the small intestine ([@bib0085]; [@bib0285]; [@bib0405]) without actually affecting the development of cDC precursors. Mice devoid of TF RUNX3 displayed a similar loss of ESAM^+^ cDC2s, potentially through direct interactions with RBPjk ([@bib0120]). Functionally, NOTCH2-signaling in cDCs is required for IL-23 production in the innate defense against *C. rodentium* ([@bib0405]). Moreover a reduced fraction of intestinal Th17 cells, previously associated with the lack of CD103^+^ intestinal cDC2s ([@bib0300]; [@bib0385]; [@bib0425]), was found in *Itgax-Cre Notch2^fl/fl^* mice in steady state ([@bib0285]), although others have shown that NOTCH2 signaling was dispensable to mount Th17 responses to certain bacteria ([@bib0290]; [@bib0380]). Since CD103^−^ cDC2s are not quantitively affected upon loss of *Notch2*, it is possible that the CCR2^+^CD103^−^ cDC2 subset in the intestine compensates for Th17 induction ([@bib0445]), although the *Notch* independency of this subset remains to be shown. Moreover, NOTCH2-signaling appeared to be dispensable for mounting Th2 responses against *S. mansoni* ([@bib0510]) or differentiation of peripheral Tregs ([@bib0370]). A recent study implied a role for *Notch2*-dependent cDC2s in mediating Tfh differentiation and germinal center (GC) responses in the spleen, but not in Peyer Patches ([@bib0065]). Next to the quantitative defect of splenic cDCs (*i.e.* ESAM^+^ subsets), in *Itgax-Cre Notch2^fl/fl^* mice ([@bib0405]) this effect was further ascribed to qualitative changes in gene expression of the *Notch2*-deficient cDC2s ([@bib0065]). However, the functional module targeted by NOTCH2 in cDC2s that favors Tfh priming ([@bib0065]) or determines the correct anatomical localization in the spleen ([@bib0305]; [@bib0405]) remains elusive. One concern regarding this latter study ([@bib0065]) is that the *Itgax-Cre* system reportedly causes leakiness in B and T cells ([@bib0240]; [@bib0425]) thus Tfh differentiation may be impaired due to targeting T cell-intrinsic NOTCH2-signaling ([@bib0025]; [@bib0110]). Therefore, future studies will have to examine the DC-intrinsic role of *Notch2* in these observations by using more specific conditional deletion models, chimeras and/or *ex vivo* assays with purified subsets. Moreover, it remains to be shown whether cDC2s are involved in a *Notch2*-dependent way in Tfh differentiation in humans as observed in mice ([@bib0135]). Next to NOTCH instruction, splenic ESAM^+^ and intestinal CD103^+^ cDC2s also rely on downstream LTβR signaling through ligands provided by the local environment ([@bib0220]; [@bib0405]; [@bib0545]), but how both pathways interact remains to be elucidated. Interestingly, in order to correctly localize in the marginal zone bridging channels NOTCH2- and LTβR-dependent cDC2s require expression of chemokine receptor Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2, encoded by *Gpr183*) ([@bib0175]; [@bib0580]). Since the loss of splenic CD4^+^ cDC2s in *Gpr183*-deficient mice could be rescued by LTβR-agonism ([@bib0580]), it is tempting to speculate that EBI2 drives the positioning of cDC2s into a niche that provides NOTCH and LTβR ligands. Therefore it will be interesting to assess the role of NOTCHsignaling in the anatomical positioning of DCs in future research.

Next to cDC2s, *Notch2*-deficiency also affected the terminal maturation of cDC1s in the spleen ([@bib0285]; [@bib0405]). Given the key role of NOTCH signaling in cDC progenitors for terminal differentiation, an alternative *in vitro* 'cDC1′ culture system for both mouse and human was recently developed that uses the FLT3L system ([@bib0360]) in combination with a stromal cell line (OP9) expressing DLL1 ([@bib0235]). While pDC development was largely abolished, these *in vitro* generated cDC1s more closely aligned with their primary counterparts ([@bib0235]), further emphasizing the key role of NOTCH signaling in terminal cDC differentiation. Another *in vitro* differentiation method similarly showed that NOTCH signaling in a GM-CSF system promoted cDC1 generation from human CD34^+^ precursors ([@bib0045]).

8. Tbet {#sec0040}
=======

Although typically thought of as a TF associated with T helper cell and innate lymphoid cell (ILC) subsets, recently, Tbet expression, reported through the use of *Tbx21*^RFP−Cre^ mice, has also been suggested to delineate two subsets of cDC2s ([@bib0070]), with those cDC2s expressing Tbet being termed cDC2As, while cDC2Bs lacked expression of this TF ([@bib0070]). Notably, this is not the first time *Tbet* expression has been reported in cDC2s ([@bib0315]; [@bib0550]). Functionally, these two populations were also suggested to be distinct, with cDC2As being more anti-inflammatory than their cDC2B counterparts ([@bib0070]). However, this appears somewhat at odds with the original studies suggesting that lack of *Tbet* expression in cDCs protected mice from collagen antibody induced arthritis ([@bib0550]) and that *Tbet* expression was required for IFN-γ production by cDCs ([@bib0315]). While IFN-γ production from cDC2As and cDC2Bs was not assessed in the recent study, preventing the direct comparison, the authors found that cDC2Bs were better at inducing IFN-γ^+^ Th1 cells in non-polarizing conditions than cDC2As (although levels of IFN-γ measured were relatively low) ([@bib0070]), which was previously attributed to the Tbet-dependent DCs ([@bib0315]; [@bib0550]). However, Brown and colleagues also observed that IFN-γ promoted *Tbet* expression in cDC2s ([@bib0070]). As the original studies used total CD11c^+^MHCII^+^ cells from WT or Tbet KO mice and did not discriminate Tbet^+^ from Tbet- cDCs, one possible hypothesis to explain this discrepancy, could be that Tbet-expressing cDC2As may promote IFN-γ production from cDC2Bs which in turn promote cDC2As creating a loop to ensure sufficient IFN-γ production from cDC2s when required. However, this remains to be formally investigated.

Although the proportions of cDC2As and cDC2Bs differed, both subsets were identified across several murine tissues. Focusing on those found in the murine spleen, despite an enrichment for binding sites of *Rbpj* and *Runx* in cDC2As suggesting a role for NOTCH signaling, the authors concluded that Tbet expression did not perfectly correlate with ESAM expression, although further investigation may be warranted based on mRNA expression profiles ([@bib0070]). Additionally, while CLEC10A and CLEC12A could be used to further distinguish cDC2Bs into different fractions, no perfect markers were reported to accurately distinguish between cDC2As and cDC2Bs ([@bib0070]). The presence of further subsets of cDC2Bs, also suggests there could be further heterogeneity within the population not accounted for by Tbet expression. For example, despite being expressed across cDC2As and cDC2Bs ([@bib0070]), loss of KLF4 selectively affects CLEC12A^+^ cDC2Bs in the spleen ([@bib0510] and reviewed in detail in [@bib0355]). In addition, it remains to be seen how traditional markers used to delineate cDC2 subsets in other tissues, for example CD103 in the intestine, fair when it comes to dividing the Tbet^+^ and Tbet^−^ fractions.

Despite the potential for further heterogeneity within the cDC2s, intriguingly, ATAC-Seq analysis revealed that cDC2As were enriched for binding sites for ID2 and NFIL3 when compared with cDC2Bs ([@bib0070]), thus given the relationship identified by the lab of Ken Murphy between these TFs and ZEB2 ([@bib0030]) it is tempting to speculate that Tbet expression could delineate the subset of cDC2s existing independently of ZEB2 expression ([@bib0450]; [@bib0570]), as NFIL3 would inhibit ZEebBEBEB2 expression which would in turn enable ID2 to be expressed. Potentially fitting with this hypothesis, when the authors compared human and murine splenic cDC2s to find counterparts, ZEB2 was one of the defining TFs found to overlap between human and murine cDC2Bs ([@bib0070]). Additionally *Zeb2* expression level does seem to distinguish between two cDC2s subsets in the murine spleen (unpublished data) however both subsets express *Zeb2* compared with cDC1s ([@bib0440] and unpublished data), perhaps this could be explained by a lower expression of NFIL3 in cDC2s than cDC1s. Indeed, this requires a further, more in-depth examination.

As mentioned above cDC2A and cDC2B counterparts were also identified in human splenic tissue, expressing CLEC4A and CLEC10A respectively, where they appeared to have similar functional properties to those in the mouse ([@bib0070]). Notably, CLEC10A^−^CLEC4A^+^ cDC2As were only found in the spleen and not in human PBMCs highlighting the need to also examine human tissue ([@bib0070]). While Tbet^+^ cDC2 equivalents were not found in human blood in this study, many recent studies have also highlighted a significant amount of heterogeneity in the cDC2 populations present within PBMCs ([@bib0140]; [@bib0210]; [@bib0455]; [@bib0535]). This suggests that, similar to the mouse, Tbet expression alone is likely not sufficient to explain all cDC2 heterogeneity in humans. The most recent study, upon bringing together all this data, proposed that there are two main cDC2 subsets present within the PBMC population based on expression of CD5 and CD163 which were termed cDC2 (CD5^-^) and cDC3 (CD5^+^CD163^+^). Here, the cDC3 population were identified to be the most inflammatory and fitting with this were also increased in proportion in SLE patients ([@bib0140]). While NOTCH2 was more highly expressed than KLF4 in the cDC3s ([@bib0140]), which TFs may specify these populations remains an open question for the future. However, with their shared expression of NOTCH, the link between the cDC3s and cDC2As also requires closer attention.

9. Conclusion {#sec0045}
=============

In the last decade significant progress has been made in our understanding of DC development and the different mature cDC populations across species and tissues ([Fig. 1](#fig0005){ref-type="fig"}). Although cDCs are commonly divided in two main lineages (cDC1s and cDC2s) based on ontogeny ([@bib0200]) and relating to function and phenotype, it has become apparent that the cDC2s, still represent a heterogeneous population. This heterogeneity is furthermore reflected by the differential reliance on certain TFs, depending on the tissue and/or event that disrupts homeostasis. While a set of TFs appear to be required for the development of the entire cDC1 (*e.g. Irf8* [@bib0475]) or pDC (*e.g. Tcf4, Zeb2,* [@bib0095]; [@bib0450]; [@bib0570]) lineages, no single transcriptional regulator has yet been identified that is essential for cDC2 development or maintenance. However, this is perhaps not surprising given the level of heterogeneity observed within this populations. Future research will need to further consider and define the contextual signals that influence the transcriptional program of different subsets of cDC2s in any specific location as perhaps similar to what is seen for macrophages ([@bib0275]), local environmental features may be key in understanding these populations. Moreover, whether the heterogeneity in transcriptional program within the cDC subsets, and in particular cDC2s, relates to specific differentiation programs induced in the primed T cells will have to be determined by future studies. A better understanding of the transcriptional and functional adaptation cDC subtypes will ultimately provide a basis for better therapeutic strategies in humans.Fig. 1Recent advances in cDC fate specification by Transcription Factors.Summary figure detailing recent advances in our understanding of transcriptional control of DC fate, highlighting remaining unknowns and main questions for the future. cDC1s develop from CDPs through pre-cDC1 intermediates. In mice, progression to cDC1 is achieved through increasing expression of IRF8 and switching from the +41 kb enhancer to the +32 kb enhancer at the pre-cDC stage. cDC1s express IRF8, BATF3, ID2, NFIL3 (red arrows) and absolutely require IRF8 (maintained through BATF3 and IRF8 autoactivation) for their development and maintenance. Expression of NFIL3, inhibits ZEB2 expression which in turn enables ID2 expression, normally repressed by ZEB2. Like cDC1s, cDC2s develop from CDPs but *via* a pre-cDC2 intermediate. There is still much to learn regarding cDC2s. Typically IRF4 is thought of as the main cDC2 TF in mice, however, it is not required for the development of all subsets, but may instead be important for survival and/or migration of specific subsets. In recent years, considerable heterogeneity has been demonstrated within the cDC2 population including the recent description of Tbet^+^ and Tbet^−^ cDC2s termed cDC2As and cDC2Bs respectively identified in mouse and human spleen. To date no distinct precursors for these subsets have been identified. In mice, cDC2As appear to also express and require NOTCH signaling being enriched for Rbpj and Runx binding sites. Whether Tbet is absolutely required for cDC2As remains to be studied. Some evidence suggests murine cDC2Bs (or a subset thereof), may require ZEB2 for their development but this remains to be directly investigated. Clec12A^+^ cDC2Bs, one subset of cDC2Bs, have been shown to require KLF4 in mice. Requirements for the other subsets remain to be studied. In human PBMCs, a pro-inflammatory cDC3 population has also recently been described, the TFs mediating this population and the precise progenitor remain to be identified however, they were shown to express higher NOTCH2 than KLF4. Thus the relationship of these cDC3s to cDC2As requires further investigation. Key questions for the future, especially related to heterogeneity within the cDC2 lineage, including understanding the role of the tissue microenvironment in cDC2 biology. How many distinct populations of cDC2s are there? Are there different subsets based on tissue? Do distinct TFs play a role in each tissue to generate the final cDC2 phenotype? Are cDC2 subsets arising from distinct developmental pathways or do they represent alternative activation states? Understanding this, will be a main goal in the coming years.Fig. 1
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